Compare UHT & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHT | VALN |
|---|---|---|
| Founded | 1986 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.5M | 653.3M |
| IPO Year | 1995 | 2021 |
| Metric | UHT | VALN |
|---|---|---|
| Price | $38.56 | $6.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $43.00 | $15.50 |
| AVG Volume (30 Days) | ★ 82.8K | 28.1K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $99,190,000.00 | N/A |
| Revenue This Year | $2.12 | N/A |
| Revenue Next Year | $2.94 | $93.87 |
| P/E Ratio | $48.96 | ★ N/A |
| Revenue Growth | ★ 0.18 | N/A |
| 52 Week Low | $35.26 | $4.75 |
| 52 Week High | $46.30 | $12.23 |
| Indicator | UHT | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 32.06 | 40.11 |
| Support Level | $38.11 | $5.10 |
| Resistance Level | $40.90 | $6.42 |
| Average True Range (ATR) | 0.77 | 0.20 |
| MACD | -0.20 | -0.10 |
| Stochastic Oscillator | 10.94 | 9.04 |
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.